PLoS ONE (Jan 2022)

Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: A Swedish observational study.

  • Hanna Brattgård,
  • Per Björkman,
  • Piotr Nowak,
  • Carl Johan Treutiger,
  • Magnus Gisslén,
  • Olof Elvstam

DOI
https://doi.org/10.1371/journal.pone.0268540
Journal volume & issue
Vol. 17, no. 5
p. e0268540

Abstract

Read online

ObjectiveLow-level viraemia (LLV) occurs in some people with HIV (PWH) receiving antiretroviral therapy (ART) and has been linked to inferior treatment outcomes. We investigated factors associated with LLV in a nationwide cohort of Swedish PWH starting ART.MethodsParticipants were identified from the InfCareHIV register, with the following inclusion criteria: ART initiation 2006-2017, age >15 years, ≥4 viral load (VL) results available and no documented treatment interruptions or virologic failure (≥2 consecutive VL ≥200 copies/ml) during follow-up. Starting from 6 months after ART initiation, participants were followed for 24 months and categorised as viral suppression (VS; VL ResultsAmong 3383 participants, 3132 (92.6%) had VS and 251 (7.4%) had LLV. In univariable analyses, factors associated with LLV were male sex, higher age, lower pre-ART CD4 count, higher pre-ART VL and ART regimen. After adjustment, the following factors were associated with LLV (adjusted odds ratio; 95% confidence interval): male sex (1.6; 1.1-2.3), higher pre-ART VL (2.7; 2.2-3.3), pre-ART CD4 count ConclusionAmong Swedish PWH, LLV during ART was associated with markers of HIV disease severity before starting ART, male sex, injecting drug use and use of PI-based or non-standard ART regimens.